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ABSTRACT Activation of the complement system is a
key event in the pathogenesis of sepsis. Nevertheless,
the exact mechanisms remain inadequately understood.
In the current study, we examined the role of comple-
ment C3 and C5 in sepsis in wild-type and C3- or
C5-deficient mice induced by cecal ligation and punc-
ture. When compared to wild-type mice, C5/ showed
identical survival, and C3/ presented significantly
reduced survival. Interestingly, this was associated with
significant decreases in plasma levels of proinflamma-
tory mediators. Moreover, although septic C3/ ani-
mals displayed a 10-fold increase of blood-borne bac-
teria, C5/ animals exhibited a 400-fold increase in
bacteremia when compared to wild-type mice. These
effects were linked to the inability of C5/ mice to
assemble the terminal membrane attack complex
(MAC), as determined by complement hemolytic activ-
ity (CH-50). Surprisingly, although negative control
C3/ mice failed to generate the MAC, significant
increases of MAC formation was found in septic C3/
mice. In conclusion, our data corroborate that hemo-
lytic complement activity is essential for control of
bacteremia in septic mice. Thus, during sepsis, block-
ade of C5a or its receptors (rather than C5) seems a
more promising strategy, because C5a-blockade still
allows for MAC formation while the adverse effects of
C5a are prevented.—Flierl, M. A., Rittirsch, D.,
Nadeau, B. A., Day, D. E., Zetoune, F. S., Sarma, J. V.,
Huber-Lang, M. S., Ward, P. A. Functions of the
complement components C3 and C5 during sepsis.
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Sepsis remains an enigmatic, poorly understood dis-
ease (1). It is now becoming increasingly clear that
sepsis might not be a disease per se but represents a
complex accumulation of symptoms forming a multi-
faceted entity that can be described only by basic
clinical parameters (2). However, these crude defini-
tions fail to be consistent, because patients might
present with either hyperthermia or hypothermia, leu-
kocytosis or leukopenia, bacteremia or lack of bactere-
mia (2, 3). Thus, some clinicians preferably refer to this
complex of symptoms as “sepsis syndrome.” It is of
concern that doctors have seen a rapid increase in
hospitalization and mortality rates for severe sepsis in
the United States between 1993 and 2003 while mortal-
ity rates only slightly decreased (4). During this 11-year
period, the hospitalization rate has almost doubled and
is considerably higher than it has been previously
predicted, making septicemia now the 10th leading
cause of death in the United States. (5).
Encroachment of pathogens prompts the comple-
ment cascade, which plays a decisive role in the host’s
immune response (1, 6). Its activation can be triggered
via 3 different pathways, converging to form the C3-
convertase, which cleaves C3 into C3a and the opsoniz-
ing C3b (7, 8). The C5-convertase subsequently cleaves
C5 into the anaphylatoxin C5a and C5b and thereby
initiates the formation of the terminal “membrane
attack complex” (MAC), consisting of C5b, C6, C7, C8,
and C9. However, during sepsis, when complement is
excessively activated, the initially beneficial effects can
rapidly turn into a severe threat to the host. In partic-
ular, disproportionately elevated levels of the anaphy-
latoxin C5a have been described as “too much of a
good thing” (9) and to reveal a “dark side in sepsis”
(10), contributing to immunoparalysis (11), multior-
gan dysfunction (12), thymocyte apoptosis (13, 14),
and deterioration of the coagulatory/fibrinolytic sys-
tem (15). Clinical studies have confirmed elevated
levels of complement activation products during sepsis,
which have been linked to poor outcome (16–19).
Accordingly, C5a blockade has been shown to be
protective in cecal ligation and puncture (CLP) -in-
duced sepsis (20) and to prevent multiorgan failure in
septic rats (12, 21, 22). On the other hand, mice
deficient for C3 have been described to show higher
susceptibility to gram-negative sepsis and endotoxin
shock (23, 24). Emerging evidence also suggests that
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C3a might have anti-inflammatory properties in addi-
tion to its proinflammatory functions (24).
In the current study, we sought to evaluate the
impact of the complement components C3 and C5 on
inflammation and bacterial clearance, including the
underlying mechanisms during experimental sepsis us-
ing C3- or C5-knockout mice.
MATERIALS AND METHODS
Experimental sepsis
All procedures were performed in accordance with the Na-
tional Institutes of Health guidelines and University Commit-
tee on Use and Care of Animals, University of Michigan.
Specific pathogen-free, 9- to 10-wk-old male wild-type mice
(WT; Jackson Laboratories, Bar Harbor, ME, USA), C3/
mice (as described previously; ref. 25) or C5/ mice (con-
genic strains B10.D2/oSn and B10.D2/nSn; Jackson Laborato-
ries) were used. All mice were on a C57BL/6 background.
Intraperitoneal ketamine (100 mg/kg body weight) (Fort
Dodge Animal Health, Fort Dodge, IA, USA) was used for
anesthesia and intraperitoneal xylazine (13 mg/kg body
weight) (Bayer Corp., Shawnee Mission, KS, USA) for seda-
tion. Experimental sepsis was induced by CLP as described
previously (26). Briefly, after abdominal midline incision, the
cecum was exposed, ligated, and punctured through and
through with a 19-gauge needle, and a small portion of feces
was pressed out to ensure persistence of the punctures. After
repositioning of the bowel, the abdomen was closed in layers
using 6-0 surgical sutures (Ethicon Inc., Somerville, NJ, USA)
and metallic clips. Before and after the surgery, animals had
unrestricted access to food and water. To induce intermedi-
ate-grade CLP, 50% of the cecum was ligated, whereas,
during high-grade CLP, 75% of the cecum was ligated.
Kaplan-Meier survival curves were analyzed for WT, C3/,
and C5/ mice (n15/group).
Plasma collection
At given time points after CLP, whole blood was collected by
cardiac puncture into syringes containing anticoagulant ci-
trate dextrose (ACD; Baxter, Deerfield, IL, USA) in a 9:1
ratio. Samples were centrifuged (2500 rpm, 10 min, 4°C);
plasma was obtained and immediately stored at 80°C until
further analysis.
Cytokine/chemokine measurements
Plasma was harvested as described above. The following
mouse ELISA kits were used: IL-1, IL-6, MCP-1, MIP-2,
TNF-, IL-10, and sTNF RII (all R&D Systems, Minneapolis,
MN, USA). Measurements were performed according to the
manufacturer’s protocols. Antibodies for IL-1Ra were ob-
tained from R&D Systems, and an ELISA was established
using the same protocol as for the commercially available kits.
For quantification of HMGB1 in mouse plasma, a commer-
cially available ELISA assay was used (Shino-Test Corporation,
Kanagawa, Japan).
Determination of colony-forming units (CFUs) in blood
Blood was obtained by cardiac puncture and was drawn into
syringes containing 10% citrate. Following appropriate dilu-
tion in 0.9% saline, 100 l samples were plated in duplicates
on 5% sheep blood agar (Remel, Lenexa, KS, USA) and
incubated for 24 h at 37°C under aerobic conditions. CFUs
were then determined and multiplied by the dilution factor.
Assessment of neutrophil counts
Plasma was obtained by cardiac puncture and diluted 1:10 in
PBS containing 5% BSA. Samples were then analyzed for
neutrophil concentrations using a Coulter counter (ADVIA
120 Hematology System; Bayer, Norwood, MA, USA).
Depletion of the complement component 6 (C6)
C6 was depleted as described previously (27). Briefly, WT
mice were injected with 40 g of polyclonal anti-mouse C6
(Cell Sciences, Canton, MA, USA) intraperitoneally daily for
5 consecutive days.
ELISA measurements of mouse C5a
Plasma levels of mouse C5a were determined as described
previously (28–30). As capture antibody, purified monoclo-
nal anti-mouse C5a IgG (5 g/ml, BD Pharmingen, San
Diego, CA, USA) was used. After blocking, diluted plasma
samples and recombinant mouse C5a (as standards) were
applied, and biotinylated monoclonal anti-mouse C5a anti-
body (500 ng/ml; BD Pharmingen) was used for detection.
Serum collection
Whole blood was collected by cardiac puncture and pipetted
into microtubes specially prepared for serum collection
(Sarstedt, Nu¨mbrecht, Germany). Serum was obtained ac-
cording to the manufacturer’s protocol and stored at 80°C
until further analysis.
Hemolytic complement assay (CH-50)
Hemolytic activity of mouse serum was assessed as described
previously (31). Briefly, rabbit red blood cells (Colorado
Serum Company, Denver, CO, USA) were sensitized with goat
antiserum to rabbit red blood cells (MP Biomedicals, Solon,
OH, USA) and exposed at 30°C for 60 min to serial dilutions
of serum samples in gelatin veronal buffer containing Ca2/
Mg2 (Sigma, St. Louis, MO, USA). Following a centrifuga-
tion step (2500 g, 5 min), absorbance of the supernatant fluid
was measured at 405 nm, and concentration inducing 50% of
hemolysis (CH-50) was determined. For some experiments,
serum was heat inactivated by 30 min incubation at 56°C.
Measurement of thrombin activity
We performed the thrombin assay as described previously
(30). Briefly, plasma was obtained at indicated time points by
cardiac puncture. S-2238 (H-d-phenylalanyl-l-pipecolyl-l-argi-
nine-p-nitroaniline dihydrochloride; DiaPharma, West Ches-
ter, OH, USA) was used as a substrate. After thrombin
cleavage of the substrate, the amount of p-nitroaniline dihy-
drochloride (pNA) formed was measured by absorbance at
405 nm in a kinetic profile. A standard curve was generated
using known amounts of thrombin (Sigma-Aldrich), and
corresponding pNA formed and the activity present in the
sample were determined from the standard curve. We per-
formed the assay in the presence of aprotinin (Roche, Indi-
anapolis, IN, USA) to inhibit proteinase activities other than
that of thrombin.
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Statistical analysis
All values are expressed as means  se. Data were analyzed
with a 1-way ANOVA, and individual group means were then
compared with a Student-Newman-Keuls test. Differences
were considered significant when P  0.05. For analysis of
survival curves, log-rank and 2 log-rank tests were used.
Outcomes in different animals were compared using 	2 and
Fisher’s exact tests.
RESULTS
Absence of C3 decreases survival whereas lack of C5
does not alter survival during experimental sepsis
Intermediate-grade CLP was employed, in which 50%
of the cecum was ligated, resulting in a 40–50% survival
over a 9 day period. Results derived from intermediate-
grade sepsis are described in Fig. 1A. Survival by day 9
was 46% in WT mice, 14% in C3/ littermates, and
43% in C5/ animals.
A recent report illustrated that there are striking
differences between a moderate and severe version of
CLP (32). Therefore, we also employed the more
severe form of CLP. In this high-grade version of CLP,
75% of the cecum was ligated, resulting in 100%
lethality by day 3. As illustrated in Fig. 1B, all animals
succumbed to CLP within 54 h. Despite this lack of
difference in the overall survival between C5/,
C3/, and WT animals, C3/ mice seemed to be the
most susceptible to the lethal consequences of sepsis. In
summary, in intermediate-grade as well as high-grade
sepsis, no significant difference was seen in survival
between WT mice and C5/ mice, whereas C3/
were more susceptible to CLP challenge.
C3 and C5 deficiency diminishes plasma levels of
proinflammatory cytokines and chemokines during
CLP-induced sepsis
WT, C3/, and C5/ animals were subjected to
intermediate-grade CLP, and blood samples were col-
lected by cardiac puncture 24 h after CLP because
cytokines and chemokines have been shown to peak
24 h after initiation of CLP sepsis (unpublished data).
Plasma was analyzed by ELISA. Table 1 displays changes
(as percentage) in mediator levels obtained from septic
C3/ and C5/ mice in comparison to septic WT
littermates. With the exception of TNF- and HMGB1,
the levels of proinflammatory mediators (IL-1, IL-6,
MCP-1, and MIP-2) were significantly decreased in C3-
and C5-deficient animals during CLP-induced sepsis.
The plasma levels of the anti-inflammatory mediators
IL-1 receptor antagonist (IL-1Ra), soluble TNF- recep-
tor II (sTNF RII), and IL-10 were significantly elevated
in C3-deficient mice, whereas IL-1Ra and IL-10 levels
were significantly decreased in animals lacking C5. In
summary, the inflammatory response as indicated by
the systemic release of cytokines/chemokines is widely
dampened in the absence of C3 or C5. However, the
reduction of plasma mediators during sepsis is not
reflected in survival rates.
Figure 1. Survival of WT, C3/, and C5/ mice following
CLP. Mice were subjected to CLP. Kaplan-Meier survival
curves were analyzed for WT, C3/, and C5/ mice (n15
per group and condition). Intermediate-grade CLP (A) was
initiated by ligation of 50% of the cecum, whereas during
high-grade CLP (B), 75% of the cecum was ligated.
TABLE 1. Plasmatic inflammatory mediators following CLP
Mediator
Change (%)
C3
/ C5
/
IL-1 90  6* 89  5*
IL-6 53  13* 60  11*
MCP-1 65  13* 36  9*
MIP-2 37  8* 53  16*
TNF- 11  26 64  30
HMGB-1 6  23 15  29
IL-1Ra 811  141* 24  37
IL-10 64  85 72  11*
sTNF RII 119  12* 2  5
Data presented as mean  se; change vs. 24 h CLP in WT mice.
Negative and positive control values (pg/ml): IL-1: 35  1, 882 
200; TNF: 19 2, 147 37; IL-10: 10 1, 217 56; IL-6: 240 10,
603  73; MCP-1: 40  10, 2300  300; MIP-2: 860  30, 66,500 
2700; HMGB-1: 4700  1700, 25,300  6900; IL-1Ra: 480  10,
2100  600; sTNF RII: 3000  200, 9400  400. *P 
 0.05 vs. 24 h
CLP in WT mice.
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Lack of C5 and C3 greatly impairs bacterial clearance
during sepsis
To evaluate whether C3- and C5-deficient animals
displayed altered systemic bacterial clearance due to an
inability to form the terminal MAC, we first sought to
identify the peak of systemic CFUs in blood following
CLP. WT mice were subjected to intermediate-grade
CLP, and blood samples were obtained 0, 6, 12, 24, and
48 h after induction of CLP, plated on sheep-blood
agar, and incubated for 24 h under aerobic conditions.
As shown in Fig. 2A, systemic CFUs peaked 24 and 48 h
after CLP. Therefore, we chose 24 h post-CLP for all
subsequent CFU experiments. WT, C3/, and C5/
animals were subjected to CLP, and blood samples
obtained after 24 h were evaluated for CFUs. WT mice
displayed a significant increase of CFUs following sepsis
challenge (Fig. 2B). Septic C3/ animals showed a
4-fold increase in levels when compared to WT litter-
mates (P
0.01), whereas septic C5/ mice had signif-
icantly increased systemic CFUs, displaying a 400-fold
increase when compared to WT littermates and a
100-fold increase over C3/ mice (Fig. 2B; P
0.01 vs.
WT and C3/). To determine whether these signifi-
cant increases in CFUs were caused by the absence of
hemolytic complement activity, WT mice were C6 de-
pleted with a neutralizing antibody (resulting in a 65%
reduction of hemolytic activity; ref. 27) and then sub-
jected to CLP. CFUs were evaluated 24 h thereafter. As
demonstrated in Fig. 2C, C6-depleted animals exhib-
ited significant increases in CFUs (10-fold) when com-
pared to WT mice, suggesting that the absence of the
MAC significantly increases CFUs during CLP. Blood
neutrophil counts were determined in WT, C3/, and
C5/ mice. Although there were no significant
changes of neutrophil numbers between WT, C3/,
and C5/ negative control animals, septic WT and
C3/ mice displayed statistically significant increases
of blood neutrophils. In sharp contrast, C5/ mice
revealed severe neutropenia following CLP (Fig. 2D).
Finally, in plasma from WT mice obtained 24 h after
CLP, significantly elevated levels of C5a (Fig. 2E) were
seen. Interestingly, C3/ mice had similarly increased
levels of C5a (Fig. 2E), possibly triggered via a newly
discovered complement activation pathway involving
thrombin (30). As shown in Fig. 3, there may be a
“shortcut” in activation of complement, because septic
C3/ mice displayed significantly increased thrombin
activity when compared to WT littermates. As ex-
pected, C5/ mice failed to generate C5a during
sepsis with plasma levels ranging at baseline 24 h after
CLP (Fig. 2E).
Absence of C5 but not C3 deficiency results in
decreased hemolytic complement activity (CH-50)
To evaluate whether the reduced capability to form the
MAC might be related to the extent of the bacterial
Figure 2. Analysis of CFUs, neu-
trophil counts, and plasmatic
C5a levels in septic WT, C3/,
and C5/ mice. A) Blood sam-
ples were harvested by cardiac
puncture 0, 6, 12, 24, and 48 h
after induction of CLP, plated on
sheep-blood agar, incubated un-
der aerobic conditions and ana-
lyzed for CFUs. B) Comparison
of CFUs in negative control WT
mice or WT, C3/, and C5/
mice 24 h after CLP. C) CFU
levels comparing WT and C6-
depleted animals under negative
control conditions or 24 h after CLP. D) Neutrophil counts were obtained from WT, C3/, and C5/ mice under negative
control conditions or 24 h after initiation of CLP. E) Plasma levels of C5a in WT, C3/, and C5/ mice following CLP as
determined by ELISA.
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load in the blood compartment after CLP, sera from WT,
C3/, C5/, and C6-depleted mice were analyzed for
their hemolytic activity by CH-50. This assay determines
the exact serum dilution, which lyses 50% of sensitized
rabbit red blood cells. As expected, WT mice displayed a
robust left shift of the CH-50 curve 24 h after CLP,
indicating severe complement consumption (Fig. 4A). As
expected, hemolytic activity was severely impaired in
C3/ negative control mice (Fig. 4B). However, follow-
ing CLP, serum from C3/ mice exhibited a right shift
(Fig. 4B), indicating that septic C3/ mice are able to
produce hemolytic activity, which is in line with the
observation that C3/ mice generated C5a after CLP
(Fig. 2E). To exclude assay-dependent variation, we heat-
inactivated sera obtained from septic C3/ mice and
subjected them to CH-50 analysis (Fig. 4B). As expected,
no hemolytic activity was found. In contrast, C5/ ani-
mals failed to display hemolytic complement activity un-
der either negative control or septic conditions (Fig. 4C).
In additional experiments, CH-50 was assessed using sera
from C6-depleted mice. Although preIgG-treated mice
demonstrated a typical WT CH-50 curve, C6-depleted
animals showed a significant left shift of the CH-50 curve
(Fig. 4D), indicating that the hemolytic complement
ability in C6-depleted mice was significantly reduced.
Heat-inactivated serum obtained from C6-depleted ani-
mals failed to show any hemolytic activity (Fig. 4D). In a
second set of experiments, C6-depleted WT mice sub-
jected to CLP showed a further left shift in the CH-50
when compared to non-CLP C6-depleted mice (Fig. 4E).
Figure 4F summarizes the actual CH-50 values as means
se and displays significant differences between CH-50
curves. Most strikingly, C3/ mice failed to generate
hemolytic complement activity under negative control
conditions but were able to create significant hemolysis
following CLP-induced sepsis, perhaps because of in-
creased plasma activity of thrombin (Fig. 3).
DISCUSSION
Recent research clearly indicates that the sepsis syn-
drome involves a complex and intricate interplay of
Figure 3. Analysis of thrombin activity in WT and C3/ mice
following CLP. Plasma was obtained from C3/ or WT mice
by cardiac puncture and subjected to analysis for thrombin
activity as a function of time after CLP.
Figure 4. Analysis of serum complement hemolytic activity (CH-50) in healthy and septic WT, C6-depleted, C3/, and C5/
mice. Sera were obtained by cardiac puncture and subjected to CH-50 analysis as described in the Methods. A–C) Analysis of
wild-type (A), C3/ (B), or C5/ (C) animals under negative control and septic conditions. D) Effect of C6-depleting
antibody or isotype IgG on CH-50 values. E) Comparison of CH-50 values of C6-depleted mice under negative control conditions
or following CLP. F) Actual CH-50 values of the curves A–E, including display of statistical differences.
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various endogenous cascade systems. In the present
study, we subjected WT mice and mice deficient in
complement C3 or C5 to experimental sepsis in order
to further define the role of these complement compo-
nents during CLP.
Surprisingly, C5/ mice displayed similar survival
when compared to WT animals, although excessive
levels of the cleavage product of C5, C5a, play a
detrimental role during sepsis (12, 20–22). We found
in the present study that, during experimental sepsis,
absence of C5 or C3 greatly enhanced bacteremia
(400- and 4-fold, respectively) in comparison to WT
animals (Fig. 2B). Once microbes enter the blood-
stream, various components of the activated comple-
ment system, such as C1q, C3b/iC3b, C4b, and man-
nose-binding lectin, rapidly opsonize these pathogens
(33). This opsonization of pathogens helps bind bacte-
ria to the complement receptors 1 (CR1) and 3 (CR3,
CD11b/CD18) expressed on leukocytes (34), inducing
phagocytosis and oxidative burst. C3, C5, C5a, and
C5aR have been shown to be critically involved in the
up-regulation of the phagocytosis receptor CD11b to-
gether with induction of the oxidative burst, because
blockade of any of these components leads to pro-
nounced inhibition of phagocytosis and oxidative burst
(35, 36). Thus, the massive bacteremia observed in the
genetic absence of C5 or C3 during sepsis (Fig. 2B)
might be related to the inability of these knockout
animals to either induce phagocytosis or initiate the
oxidative burst.
Although negative control C3/ animals failed to
show hemolytic complement activity (CH-50), sera
from septic C3/ mice showed a significant right shift
of the CH-50 curve, indicating a significantly increased
capability of complement-mediated hemolysis under
septic conditions. When these septic sera obtained
from C3/ mice were heat inactivated, this increase in
hemolytic activity was abolished (Fig. 4B). The signifi-
cant differences of blood-borne bacteria (Fig. 2B) be-
tween C3/ mice and C5/ littermates (100-fold)
might be explained by the observation that septic
C3/ mice showed full production of C5a in plasma
(similar to WT mice, Fig. 2E). This is consistent with a
recent report describing a novel pathway of comple-
ment activation, where, in the absence of C3, thrombin
can function as a C5-convertase, directly cleaving C5
into C5b and biologically active C5a (30). As shown in
Fig. 3, C3-deficient mice after CLP displayed signifi-
cantly increased thrombin activity when compared to
WT animals, indicating that this “shortcut” comple-
ment activation pathway is fully functional during CLP
sepsis. Thus, C3/ mice not only can generate C5a via
this novel pathway, but they can also produce C5b for
MAC assembly. This is underscored by our data in
Fig. 4.
In addition, the hemolytic complement activity (CH-
50) in C5/ mice was virtually absent (Fig. 4C),
suggesting that the tremendous bacterial load in septic
C5/ mice may be further accentuated by the inability
to generate C5b, a crucial component of the terminal
MAC. To confirm the role of hemolytic complement
activity in sepsis, we depleted WT mice of another
protein necessary for MAC assembly, C6, and subjected
these animals to CH-50 and CFU analysis. As expected,
C6-depleted mice displayed significantly reduced
CH-50 values (Fig. 4D) and exhibited significant in-
creases in blood-borne bacteria (Fig. 2C). In contrast
to our findings, a previous study described that
antibody-induced blockade of C5 or absence of C6
protected rats from sepsis mortality and attenuated
the bacterial load in liver and spleen after CLP (37).
The authors concluded that the MAC does not
contribute to bacterial clearance during sepsis, al-
though supportive evidence was not provided. Fur-
thermore, as suggested by the authors, it is possible
that the C6/ rats have developed unknown com-
pensatory adaptive responses.
However, many findings obtained from murine sepsis
models have failed to be translatable into clinical
efficacy, raising the question as to how valid and useful
widely used septic animal models are (38). It is gener-
ally agreed that, of all sepsis models (such as live
bacteria, endotoxin, LPS challenge, and CLP), the CLP
animal model seems to most closely resemble the
immunopathologic responses of human sepsis, includ-
ing hypothermia, decreased activity, weight loss, re-
duced hemoglobin, decreased platelet, lymphocyte,
monocyte and neutrophil counts, as well as the cyto-
kine/chemokine profile (39–41). Interestingly, we
found similarities in human case reports about patients
with hereditary deficiency of C3 or C5, who suffer from
recurrent infectious episodes. A C3-deficient patient
showed reduced CH-50 values (42), but normal com-
plement-mediated passive hemolysis (43), whereas in
C5-deficient patients, MAC-mediated hemolysis failed
to occur in either test (43, 44).
The greatly attenuated surge in proinflammatory
mediators in septic C3- or C5-deficient mice is a sur-
prising observation, challenging the pathophysiological
role of the previously described “cytokine-chemokine
storm” as a centerpiece of the systemic inflammatory
response syndrome and sepsis (45, 46). Based on the
cytokine-chemokine storm concept, several clinical tri-
als have tried to block proinflammatory cytokines (such
as TNF or IL-1) during sepsis, but none of these trials
have been successful (1). Thus, there is now increasing
evidence that the cytokine storm is less mechanistic for
sepsis and sepsis-related deaths, but might rather be an
endogenous secondary response to overwhelming in-
flammatory insult (47). Although C3/ and C5/
mice in our studies showed an ameliorated mediator
response, they ultimately encountered identical lethal-
ity in CLP-induced sepsis. Thus, as a matter of debate,
the cytokine-chemokine storm might not be linked to
septic lethality, but rather represents a resulting inflam-
matory reaction. In contrast to the broad reduction of
proinflammatory mediators in C3/ and C5/ mice,
2 anti-inflammatory mediators (IL-10 and IL-1Ra) were
found to be differently regulated in these knockout
mice. C5/ mice displayed significant reductions of
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the anti-inflammatory mediator IL-10 in contrast to
C3/ or WT mice (Table 1). It has been shown that
exogenous IL-10 reduces mortality in experimental
sepsis and that IL-10/ mice display much greater
susceptibility to endotoxemia (48 –50). Because
C5/ mice displayed significantly reduced levels of
IL-10 as well as severe bacteremia, it is tempting to
speculate whether there is a link between these two
observations.
Unexpectedly, septic C3/ mice exhibited a robust
increase of plasmatic IL-1Ra when compared to WT or
C5/ littermates (Table 1). In line with our findings
in C3/ mice (high plasma levels of IL-1Ra, increased
bacteremia, reduced CLP survival), treatment of WT
mice with IL-1Ra before CLP resulted in decreased
proinflammatory cytokine response, augmented bacte-
rial load, and increased mortality (51). Moreover, fol-
lowing endotoxemia challenge in mice, administration
of recombinant IL-1Ra was reported to partially block
increased mucosal production of C3 in the small intes-
tine (52). Furthermore, when mice were injected with
IL-1Ra, reduced serum levels of C3 was found in an
animal model of myasthenia gravis (53). However, the
association between C3 and IL-1Ra has yet to be fully
understood.
Collectively, animals seem to succumb to sepsis be-
cause of very different pathophysiological causes. Septic
WT mice encounter not only mild bacteremia (Fig. 2A,
B) and an exacerbated inflammatory mediator re-
sponse (54), but also excessive levels of C5a, resulting
in immunoparalysis of neutrophils (11). C3-deficient
mice seem to struggle with a lethal combination of
impaired bacterial clearance because of reduced
phagocytotic activity, impaired oxidative burst (35, 36),
and diminished hemolytic complement activity, as well
as C5a-induced immunoparalysis of neutrophils. Al-
though C5/ mice cannot produce C5a during sepsis,
this putative “advantage” seems to be traded off for an
overshooting, uncontrollable bacteremia because of
impaired bacterial clearance (35, 36) and deficient
bactericidal complement activity.
In conclusion, our data corroborate the importance
of the complement system in the pathogenesis of sepsis.
Bactericidal, lytic complement activity seems indispens-
able for controlling murine systemic bacterial infec-
tions. In line with a previous report in a meningococcal
model of sepsis (55), our data imply that blockade of
C5a or its receptors rather than C5 should be pursued
for complement inhibition in sepsis, because only this
strategy allows formation of the MAC, while at the same
time C5a is prevented from revealing its harmful
consequences.
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